GCOR Genencor International, (MM)

Genencor International to Present at the 23rd Annual JP Morgan Healthcare Conference PALO ALTO, Calif., Dec. 23 /PRNewswire-FirstCall/ -- Genencor International, Inc. (NASDAQ:GCOR) today announced that the company is scheduled to present at the 23rd Annual JP Morgan Healthcare Conference at 9:30 a.m. PST on Monday, January 10, 2005 at the Westin St. Francis Hotel in San Francisco, California. Jean-Jacques Bienaime, Genencor's chairman, chief executive officer and president plans to report on the company's health care strategy and the current status of Genencor's three development programs for cancer. In addition, Bienaime plans to review Genencor's bioproducts business, including an update on the commercialization progress of its new biodefense product for the neutralization of organophosphate based nerve agents, such as sarin. The live audio webcast of the presentation as well as the replay will be available at http://equityconferences.jpmorgan.com/ and the slide presentation may be accessed on the homepage at http://www.genencor.com/. About Genencor Genencor International is a diversified biotechnology company that develops and delivers innovative products and services into the health care, agri-processing, industrial and consumer markets. Using an integrated set of technology platforms, Genencor's products deliver innovative and sustainable solutions to many of the problems of everyday life. Genencor traces its history to 1982 and has grown to become a leading biotechnology company, with over $380 million in year 2003 annual revenues. Genencor has principal offices in Palo Alto, California; Rochester, New York; and Leiden, the Netherlands. DATASOURCE: Genencor International CONTACT: (Media) Valerie Tucker, +1-650-846-7571, or (Investors) Thomas Rathjen, +1-650-846-5810, both of Genencor International Web site: http://www.genencor.com/

Copyright